Chemotherapy combined with targeted therapy and immunotherapy is an option in advanced biliary tract cancer.
作者信息
Ge Penglei, Wu Yang
机构信息
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, Henan 450052, China.
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
出版信息
Therap Adv Gastroenterol. 2024 Feb 26;17:17562848241234509. doi: 10.1177/17562848241234509. eCollection 2024.
Abstract
摘要
相似文献
1
Chemotherapy combined with targeted therapy and immunotherapy is an option in advanced biliary tract cancer.化疗联合靶向治疗和免疫治疗是晚期胆管癌的一种治疗选择。
Therap Adv Gastroenterol. 2024 Feb 26;17:17562848241234509. doi: 10.1177/17562848241234509. eCollection 2024.
2
Systemic treatment options for advanced biliary tract carcinoma.晚期胆道癌的系统治疗选择。
J Gastroenterol. 2020 Oct;55(10):944-957. doi: 10.1007/s00535-020-01712-9. Epub 2020 Aug 3.
3
Current status of chemotherapy for the treatment of advanced biliary tract cancer.晚期胆道癌化疗治疗的现状。
Korean J Intern Med. 2013 Sep;28(5):515-24. doi: 10.3904/kjim.2013.28.5.515. Epub 2013 Aug 14.
4
Chemotherapy for Biliary Tract Cancer in 2021.2021年胆管癌的化疗
J Clin Med. 2021 Jul 14;10(14):3108. doi: 10.3390/jcm10143108.
5
Chemotherapy and targeted therapy for advanced biliary tract cancers: an umbrella review.晚期胆道癌的化疗和靶向治疗：伞式综述。
BMC Cancer. 2023 Apr 25;23(1):378. doi: 10.1186/s12885-023-10679-8.
6
[Significance of combination of targeted therapy and immunotherapy in conversion therapy of biliary tract cancer].[靶向治疗与免疫治疗联合在胆管癌转化治疗中的意义]
Zhonghua Wai Ke Za Zhi. 2022 Apr 1;60(4):343-350. doi: 10.3760/cma.j.cn112139-20220110-00019.
7
Current and emerging immunotherapeutic approaches for biliary tract cancers.当前和新兴的胆管癌免疫治疗方法。
Hepatobiliary Pancreat Dis Int. 2022 Oct;21(5):440-449. doi: 10.1016/j.hbpd.2022.08.015. Epub 2022 Sep 7.
8
Immunotherapy in Biliary Tract Cancers: Where Are We?胆管癌的免疫治疗：我们在哪里？
Curr Oncol Rep. 2022 Dec;24(12):1821-1828. doi: 10.1007/s11912-022-01328-7. Epub 2022 Oct 4.
9
The choice for the optimal therapy in advanced biliary tract cancers: Chemotherapy, targeted therapies or immunotherapy.晚期胆道癌最优治疗方案的选择：化疗、靶向治疗还是免疫治疗。
Pharmacol Ther. 2020 Jun;210:107517. doi: 10.1016/j.pharmthera.2020.107517. Epub 2020 Feb 25.
10
Emerging treatment strategies in hepatobiliary cancer.肝胆癌的新兴治疗策略。
Expert Rev Anticancer Ther. 2023 Mar;23(3):243-256. doi: 10.1080/14737140.2023.2183844. Epub 2023 Mar 1.
引用本文的文献
1
Camrelizumab in combination with chemotherapy and targeted therapy improves the prognosis in patients with advanced biliary tract cancer: a single-center retrospective clinical study.卡瑞利珠单抗联合化疗和靶向治疗改善晚期胆管癌患者预后：一项单中心回顾性临床研究
J Gastrointest Oncol. 2025 Apr 30;16(2):660-670. doi: 10.21037/jgo-2025-184. Epub 2025 Apr 27.
本文引用的文献
1
Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study.阿替利珠单抗、贝伐单抗联合GEMOX三联疗法治疗晚期胆管癌的疗效和安全性：一项多中心、单臂、回顾性研究
Therap Adv Gastroenterol. 2023 Mar 28;16:17562848231160630. doi: 10.1177/17562848231160630. eCollection 2023.
2
Validation study of postoperative liver failure and mortality risk scores after liver resection for perihilar cholangiocarcinoma.肝门部胆管癌肝切除术后肝功能衰竭及死亡风险评分的验证研究
Hepatobiliary Surg Nutr. 2022 Jun;11(3):375-385. doi: 10.21037/hbsn-20-660.
3
Novel biomarkers and the future of targeted therapies in cholangiocarcinoma: a narrative review.胆管癌中的新型生物标志物与靶向治疗的未来：一篇叙述性综述
Hepatobiliary Surg Nutr. 2022 Apr;11(2):253-266. doi: 10.21037/hbsn-20-475.
4
Conversion therapy of stage IVb unresectable gallbladder carcinoma.IVb期不可切除胆囊癌的转化治疗
Hepatobiliary Surg Nutr. 2022 Apr;11(2):335-337. doi: 10.21037/hbsn-22-78.
5
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.ivosidenib 治疗 IDH1 突变、化疗耐药性胆管癌（ClarIDHy）：一项多中心、随机、双盲、安慰剂对照、3 期研究。
Lancet Oncol. 2020 Jun;21(6):796-807. doi: 10.1016/S1470-2045(20)30157-1. Epub 2020 May 13.
6
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.培米替尼治疗既往治疗过的局部晚期或转移性胆管癌：一项多中心、开放标签、2 期研究。
Lancet Oncol. 2020 May;21(5):671-684. doi: 10.1016/S1470-2045(20)30109-1. Epub 2020 Mar 20.
7
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.帕博利珠单抗治疗非结直肠癌高度微卫星不稳定/错配修复缺陷型癌症患者的疗效：来自 II 期 KEYNOTE-158 研究的结果。
J Clin Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. Epub 2019 Nov 4.
8
Cancer immunotherapy using checkpoint blockade.使用免疫检查点阻断的癌症免疫疗法。
Science. 2018 Mar 23;359(6382):1350-1355. doi: 10.1126/science.aar4060. Epub 2018 Mar 22.
9
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.胆管癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2016 Sep;27(suppl 5):v28-v37. doi: 10.1093/annonc/mdw324.
10
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.顺铂联合吉西他滨与吉西他滨治疗胆管癌。
N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721.
Zotero 插件